Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: PuddleGlum who wrote (594)	1/29/1998 10:13:00 PM
From: Purebull	Respond to of 1686

Here is the upgrade news from H&Q. Purebull Biogen -2: H&Q Cites Improved Growth Of Avonex NEW YORK (Dow Jones)--Hambrecht & Quist Inc. upgraded Biogen Inc. (BGEN) to strong buy from buy. In a research note, the firm said the upgrade is based on improved growth of Biogen's Avonex product. Hambrecht & Quist raised its 1999 earnings estimate to $2.22 a share from $2. The 1998 projection remains at $1.75 a share. "Dow Jones News Service" "Copyright(c) 1998, Dow Jones & Company, Inc."

To: PuddleGlum who wrote (594)	1/29/1998 10:33:00 PM
From: Purebull	Respond to of 1686

Posted this earlier but somehow got removed. Upgrade from H&Q. Purebull. Biogen -2: H&Q Cites Improved Growth Of Avonex NEW YORK (Dow Jones)--Hambrecht & Quist Inc. upgraded Biogen Inc. (BGEN) to strong buy from buy. In a research note, the firm said the upgrade is based on improved growth of Biogen's Avonex product. Hambrecht & Quist raised its 1999 earnings estimate to $2.22 a share from $2. The 1998 projection remains at $1.75 a share. "Dow Jones News Service" "Copyright(c) 1998, Dow Jones & Company, Inc."